Clinical Trial Update: A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating nivolumab plus ipilimumab with chemotherapy versus chemotherapy alone as first-line treatment for non-small cell lung cancer; the study…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• OPDIVO (nivolumab)
• Yervoy (ipilimumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Non-Small Cell Lung Cancer | Phase 3 | Status: COMPLETED | Results posted: 2020-09-16